Disclaimer
NovusValue.com is not a broker or dealer, and none of its content represents recommendations to buy or sell securities. Information provided on the site is not intended as investment advice. Novus Value is not liable for damages from using its content, including investment losses. Past performance does not indicate future results, and information is not guaranteed for accuracy or completeness.1-Line Summary
Charles River Laboratories leads in non-clinical drug development services, enabling faster and more efficient drug discovery.
Charles River Laboratories International, Inc. is a leading global partner in drug development, specializing in non-clinical services that facilitate the entire drug discovery process. Founded in 1947, the company has evolved from its roots in laboratory animal medicine to offer a diversified portfolio including research models, discovery services, safety assessments, and manufacturing solutions. Charles River operates through three primary business segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. This structure allows them to provide integrated support to clients from the earliest stages of drug development up to regulatory considerations.
The company serves a wide range of clients, including major pharmaceutical and biotechnology firms, government agencies, and academic institutions. With operations in over 20 countries and a focus on high-quality, purpose-bred research models and a comprehensive suite of safety assessment services, Charles River is well-positioned in the biopharmaceutical landscape. The firm aims to help clients improve their operational efficiency and speed to market through continuous investment in innovation and technology, cementing its role as a critical player in the advancement of healthcare solutions.
Automaticly searches the internet using AI for the current investing thesis for Charles River Laboratories International, Inc. (CRL) and summarizes it. Only available for paid users.